Immunobiome to Participate in IPC 2024... "Introducing Probiotic-Based Pharmaceutical Development Technology"

Immunobiome, an AI-based new drug research and development company, announced on the 20th that it participated in the ‘2024 International Probiotics Conference (IPC)’ and presented its innovative technologies.

IPC is the world's largest academic conference in the field of gut health and gut microbiota, including probiotics and prebiotics. Approximately 400 probiotics experts and scientists from over 80 countries worldwide attend to share the latest industry trends and specialized knowledge. This year marks the 17th event, held from June 18 to 20 (local time) in Prague, Czech Republic.

Shinhyuk Lim, CEO of Immunobiome and professor of the Department of Life Sciences at Pohang University of Science and Technology (POSTECH), who attended the conference, led a keynote lecture and panel discussion in the fields of probiotics and immunity. He was also awarded a plaque of appreciation in recognition of his contributions to the development of the conference, having served as IPC president from 2015 to 2023.

In his keynote lecture titled “From Probiotics to Live Biotherapeutic Products: A Journey in Science and Innovation,” CEO Lim explained ▲the differences between live biotherapeutic products (LBP) and probiotics ▲the processes required for LBP development ▲the enhancement of anti-inflammatory and anticancer effects using Immunobiome’s Avatiome platform technology ▲and the current status of LBP development. During the panel discussion, he engaged with distinguished scientists to discuss issues related to LBPs and future directions.

An Immunobiome representative stated, “The Avatiome platform technology, which applies AI technology in the product development process, enables not only the analysis of correlations between genomes and candidate substances but also the selection of microbiome-based microbial therapeutic candidates for target diseases, allowing optimal clinical trial design.” They added, “At this conference, we concretely presented empirical data on how the Avatiome platform technology is applied in actual product development by utilizing the development cases of the atopic dermatitis treatment IMB001 and the autoimmune disease treatment IMB002 pipelines.”

They continued, “Based on this, we actively held meetings for joint research and development and licensing with global companies,” and added, “We will continue to participate in various international pharmaceutical and food events to promote Avatiome technology and accelerate microbiome-based new drug research and development as well as the exploration of new functionalities based on probiotics.”

This content was produced with the assistance of AI translation services.